Morningside Venture Investments is a venture capital firm based in the greater Boston area, specializing in early-stage investments in life sciences, digital health, artificial intelligence, materials, and technology sectors. Founded in 1986 as a family office for the Chan family, the firm has a long-term outlook on company-building and is committed to ethical practices. Morningside has been a pioneer in areas such as oncolytic viral therapy, mitochondrial medicine, and innate immunity, including toll-like receptors, the STING pathway, the complement cascade, and immune proteosomes.

The firm has invested in multiple companies that began as class projects of undergraduate and graduate students, demonstrating its openness to fresh ideas regardless of their origin. Morningside has a history of supporting companies through challenging times, such as backing the relaunch of Apellis Pharmaceuticals after its lead asset was returned by a pharma licensee for safety reasons. The firm believes in the importance of doing good and doing well, emphasizing that these goals go hand in hand.